SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and …
Over the last 12 months, insiders at SI-BONE, Inc. have bought $0 and sold $2.62M worth of SI-BONE, Inc. stock.
On average, over the past 5 years, insiders at SI-BONE, Inc. have bought $0 and sold $20.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 400,000 shares for transaction amount of $6M was made by Bonita David P (director) on 2018‑10‑19.
2024-11-19 | Sale | President, Commercial Ops | 2,070 0.0049% | $12.17 | $25,195 | 0.00% | ||
2024-11-18 | Sale | Chief Executive Officer | 10,048 0.0244% | $12.57 | $126,354 | 0.00% | ||
2024-11-18 | Sale | President, Commercial Ops | 3,937 0.0096% | $12.60 | $49,609 | 0.00% | ||
2024-11-18 | Sale | Chief Financial Officer | 2,439 0.006% | $12.68 | $30,937 | 0.00% | ||
2024-11-18 | Sale | director | 1,609 0.0039% | $12.43 | $20,001 | 0.00% | ||
2024-11-04 | Sale | director | 341 0.0008% | $13.55 | $4,621 | +13.32% | ||
2024-10-03 | Sale | President, Commercial Ops | 921 0.0022% | $13.60 | $12,526 | -4.55% | ||
2024-10-02 | Sale | President, Commercial Ops | 3,305 0.0078% | $13.58 | $44,877 | -2.72% | ||
2024-10-02 | Sale | Chief Financial Officer | 3,305 0.0078% | $13.58 | $44,886 | -2.72% | ||
2024-09-03 | Sale | Chief Financial Officer | 1,414 0.0035% | $16.35 | $23,119 | -13.43% | ||
2024-08-19 | Sale | President, Commercial Ops | 2,087 0.005% | $14.17 | $29,569 | +3.70% | ||
2024-08-16 | Sale | Chief Executive Officer | 9,967 0.0235% | $13.84 | $137,970 | -0.49% | ||
2024-08-16 | Sale | President, Commercial Ops | 3,905 0.0092% | $13.84 | $54,037 | -0.49% | ||
2024-08-16 | Sale | Chief Financial Officer | 2,418 0.0057% | $13.87 | $33,538 | -0.49% | ||
2024-08-16 | Sale | director | 1,580 0.0037% | $13.84 | $21,867 | -0.49% | ||
2024-08-02 | Sale | director | 343 0.0008% | $14.32 | $4,912 | -3.56% | ||
2024-07-03 | Sale | President, Commercial Ops | 920 0.0023% | $13.05 | $12,007 | 0.00% | ||
2024-07-02 | Sale | President, Commercial Ops | 3,309 0.0083% | $12.92 | $42,755 | 0.00% | ||
2024-07-02 | Sale | Chief Financial Officer | 3,309 0.0083% | $12.90 | $42,694 | 0.00% | ||
2024-06-10 | Sale | director | 341 0.0008% | $12.99 | $4,430 | +8.14% |
Skyline Venture Partners V LP | 10 percent owner | 2819985 6.7241% | $12.34 | 1 | 7 | <0.0001% |
Petersen Timothy | director | 1695036 4.0417% | $12.34 | 1 | 0 | <0.0001% |
ORBIMED ADVISORS LLC | director | 985368 2.3496% | $12.34 | 1 | 0 | <0.0001% |
Bonita David P | director | 985368 2.3496% | $12.34 | 1 | 0 | <0.0001% |
Freund John Gordon | director | 103899 0.2477% | $12.34 | 1 | 23 | <0.0001% |
Brown Advisory | $69.14M | 10.25 | 4.22M | +0.37% | +$256,010.45 | 0.09 | |
BlackRock | $64.22M | 9.52 | 3.92M | +0.41% | +$261,314.31 | <0.01 | |
OrbiMed | $51.97M | 7.7 | 3.17M | +38.47% | +$14.44M | 0.4 | |
First Light Asset Management | $40.49M | 6 | 2.47M | -2.91% | -$1.22M | 3.41 | |
The Vanguard Group | $40.33M | 5.98 | 2.46M | +1.8% | +$714,877.89 | <0.01 |